For patients with CRC and inactivation or decreased activity of APC2 gene mutation, the treatment strategy targeting FOXO4 may be an invalid choice, so mutation screening of APC genes may be a necessary prestep in CRC treatment by targeting FOXO4. Here, FOXO4 is linked to colorectal carcinoma.